Fidelio acquires Indical Bioscience

April 5, 2018

Fidelio acquires Indical Bioscience, a leading provider of diagnostic products specifically developed for veterinary specific applications.

The company develops and markets diagnostic solutions and products based on PCR (molecular) and ELISA (immunodiagnostic) technology. The products are used by laboratories primarily to indicate and diagnose viruses and bacteria in production animals, to counteract proliferation and contribute to better animal and human health.

Indical Bioscience is based in Germany and serves customers in 169 countries through its own sales force and commercial partners. Fidelio Capital acquired Indical Bioscience through a carve-out from Qiagen, a molecular diagnostic group listed on the NYSE and Frankfurt stock exchanges.

Recent news

BoNea and Akevo join Nabo

Nabo acquires BoNea and Akevo – two property management companies based in Sweden. BoNea and Akevo offer financial management services to 250 tenant-owner associations. Read the full press release here (Swedish).

Read more

Nabo expands through the acquisition of Örehus F…

Nabo has acquired Örehus Fastighetsförvaltning, a provider of financial and technical management services to tenant-owner associations. The acquisition establishes Nabo as a comprehensive service provider in southern Sweden, with a full range of services. At the same time, Örehus’ customers

Read more

Fidelio acquires Veterinary Orthopedic Implants (…

Fidelio Capital acquires a majority of the shares in VOI. VOI is a leading company within the market for veterinary orthopedic implants and instruments. The company is based in Florida, USA, and sells its products to over 40 markets world-wide.

Read more